BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

9480	Companies
185563	Keywords
117969	Articles
99399	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 09/26/2024 at 09:05, 1 year 2 months ago

BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
BioNxt Solutions Inc. updates on sublingual Cladribine drug formulation program for Multiple Sclerosis, patent applications, and investor relations activities. Company aims to revolutionize drug delivery systems for CNS diseases

Investor Relations BioNxt Solutions Inc. Multiple Sclerosis Cladribine Patent Application
BRIEF

published on 09/09/2024 at 22:35, 1 year 2 months ago

BioNxt Receives Positive International Examination Report From the European Patent Office

Multiple Sclerosis BioNxt Solutions European Patent Office Sublingual Drug Delivery Myasthenia Gravis
BRIEF

published on 09/09/2024 at 22:35, 1 year 2 months ago

BioNxt reçoit un rapport d'examen international positif de l'Office européen des brevets

Sclérose En Plaques Solutions BioNxt Office Européen Des Brevets Administration Sublinguale De Médicaments Myasthénie Grave
PRESS RELEASE

published on 09/09/2024 at 22:30, 1 year 2 months ago

BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
BioNxt Solutions Inc. receives positive international examination report from the European Patent Office for sublingual delivery patent application. Company to expand patent portfolio for neurodegenerative diseases and MS market

BioNxt Solutions Inc. Multiple Sclerosis Patent Application Neurodegenerative Diseases European Patent Office
BRIEF

published on 08/15/2024 at 09:10, 1 year 3 months ago

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

Partnership Cladribine Pharmaceutical Development BioNxt Solutions Gen-Plus GmbH
BRIEF

published on 08/15/2024 at 09:10, 1 year 3 months ago

BioNxt signe une lettre d'intention avec Gen-Plus GmbH & Co KG pour d'éventuelles collaborations commerciales

Partenariat Cladribine Développement Pharmaceutique Solutions BioNxt Gen-Plus GmbH
PRESS RELEASE

published on 08/15/2024 at 09:05, 1 year 3 months ago

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
BioNxt Solutions Inc. signs non-binding LOI with Gen-Plus GmbH & Co KG, part of Conscio Group, for potential cooperation in pharmaceutical products and clinical trials. Details to follow

Clinical Trials Pharmaceutical BioNxt Solutions Inc. LOI Gen-Plus GmbH
BRIEF

published on 07/17/2024 at 09:10, 1 year 4 months ago

BioNxt Signs Statement of Work with International CRDMO for Cladribine ODF Development

Multiple Sclerosis Pharmaceutical Development BioNxt Solutions Cladribine ODF CRDMO
BRIEF

published on 07/17/2024 at 09:10, 1 year 4 months ago

BioNxt signe une déclaration de travail avec le CRDMO international pour le développement de la cladribine ODF

Sclérose En Plaques Développement Pharmaceutique Solutions BioNxt Cladribine ODF CRDMO
PRESS RELEASE

published on 07/17/2024 at 09:05, 1 year 4 months ago

BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
BioNxt Solutions Inc. signs agreement with German CRDMO for Cladribine oral dissolvable film development program targeting the lucrative multiple sclerosis market

BioNxt Solutions Inc. Cladribine CRDMO Oral Dissolvable Film MS Market

Accesswire

Published on 12/06/2025 at 01:15, 32 minutes ago

Prospect Ridge Announces Closing of Flow-Through Unit Private Placement
Published on 12/06/2025 at 00:25, 1 hour 22 minutes ago

GMV Minerals Announces Non-Brokered Private Placement Pursuant to the Listed Issuer Financing Exemption
Published on 12/06/2025 at 00:00, 1 hour 47 minutes ago

Bird River Announces Closing of $0.10 Common Share Financing
Published on 12/05/2025 at 23:30, 2 hours 17 minutes ago

55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000
Published on 12/05/2025 at 22:50, 2 hours 57 minutes ago

Banyan Gold Grants Incentive Stock Options

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 3 hours 31 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 3 hours 35 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 6 hours 49 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 7 hours 20 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 7 hours 31 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 23:00, 2 hours 47 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 2 hours 47 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 2 hours 47 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 2 hours 47 minutes ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 8 hours 29 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible

View all LES ECHOS COMFI WIRE